Has Barry Rubin received payments from drug or device companies?

Yes. Drug and device makers reported $1,814 in general payments to Barry Rubin across 102 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Barry Rubin did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Barry Rubin come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Barry Rubin

Gastroenterology · Silver Spring, MDNPI 1770580607

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 34.3% of the total. That places this record below the midpoint for gastroenterology clinicians in MD, where the typical reported total is $2,763.

$1,814in general payments, 2019–2025

Across 102 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$622
Ferring Pharmaceuticals Inc.$240
Takeda Pharmaceuticals U.S.A., Inc.$169
Bristol Myers Squibb$137
E.r. Squibb & Sons, L.L.C.$118
Sanofi$113
plus $415 from 11 others

What the payments were for

Food & beverage$1,79899%
Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	33	$622
Ferring Pharmaceuticals Inc.	18	$240
Takeda Pharmaceuticals U.S.A., Inc.	13	$169
Bristol Myers Squibb	7	$137
E.r. Squibb & Sons, L.L.C.	1	$118
Sanofi	5	$113
Johnson & Johnson	5	$73
Intercept Pharmaceuticals, Inc.	3	$64
Braintree Laboratories, Inc.	3	$45
Pfizer	2	$43
Ardelyx, Inc.	2	$38
UCB, Inc.	2	$35
Regeneron Healthcare Solutions, Inc.	2	$30
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$27
Daiichi Sankyo Inc.	1	$24
QOL Medical, LLC	2	$21
Ironwood Pharmaceuticals, Inc	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ZEPOSIA$118

How this compares

$1,814 in reported general payments places this provider in the 40th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland →

Other gastroenterology in Silver Spring

Apurva ModiRockville$1.1M
Sergey KantsevoyBaltimore$1.1M
Anurag MaheshwariBaltimore$803K
Aline Charabaty PishvaianBaltimore$631K
Zachary BormanChevy Chase$520K
Mouen KhashabBaltimore$440K
Erica CohenChevy Chase$385K
Natarajan RavendhranCatonsville$367K
Raymond CrossBaltimore$341K
Raja TaunkAnnapolis$328K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →